The present invention relates to specific doses of and dosing regimens for
using a 1,2,4-oxadiazole benzoic acid compound in treating or preventing
diseases associated with nonsense mutations. In particular, the invention
relates to specific doses and dosing regimens for the use of
3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid in mammals
having diseases associated with nonsense mutations.